Intermittent Hypoxia-Hyperoxia Therapy Explained Simply
With intermittent hypoxia-hyperoxia therapy, one breathes alternately oxygen-poor and oxygen-rich air. The page explains in simple words what studies have shown so far — for anyone who wants an overview.
1. What It Is About
In this treatment, a person breathes alternately through a mask air with little oxygen and air with a lot of oxygen. 'Hypoxia' means oxygen deficiency, 'hyperoxia' means a lot of oxygen. The phases alternate several times in succession. The treatment is non-invasive: nothing is introduced into the body and no surgery is performed. One sits or lies during this and continues to breathe calmly.
The idea comes from altitude medicine and training research. As early as the 1990s, oxygen-poor air was used in training to enhance performance. IHHT supplements this approach with phases of high oxygen that are intended to support recovery.
The treatment is carried out in controlled sequences, usually under medical supervision. In the studies, a session usually lasted about 30 to 60 minutes. The oxygen-poor section is intended to trigger adaptations in the body; the oxygen-rich section is intended to balance it again. How long the individual sections last and how much oxygen the air contains varies from study to study.
2. What Studies Show
The treatment is best studied in older people. In a study with older patients who had several complaints, memory and attention improved in simple tests 1. In a further study with older participants, the six-minute walking distance increased more in the group with the treatment than in the group without; the other mobility tests did not differ clearly 3.
In Long COVID the treatment was tested during inpatient rehabilitation. 70 patients underwent rehabilitation; half received the treatment in addition. The six-minute walking distance improved more in this group than in the others. Shortness of breath and exhaustion also improved, but not strongly enough to be considered clear 5.
In 65 people with metabolic syndrome — that is, with overweight and unfavourable blood values — total cholesterol, LDL cholesterol and triglycerides decreased after three weeks of treatment. Two inflammatory markers in the blood also decreased. The comparison group, which breathed normal room air, showed no change 2.
In 70 people with severe overweight the treatment was tested as part of comprehensive rehabilitation. After three to four weeks physical capacity was better and lung function was also improved. Kidney and liver values also changed. Because the treatment here was part of a larger programme, its contribution cannot be separated 6.
127 patients with coronary heart disease received the treatment before bypass surgery. After the operation certain blood values that rise during stress on the heart muscle were lower. No serious adverse effects were reported 4.
It is striking that almost all controlled studies tested the treatment together with exercise, training or rehabilitation.
3. What Remains Unclear
None of the controlled studies tested the treatment alone. It is almost always combined with exercise therapy, training or rehabilitation. Which part of the improvements is attributable to the treatment cannot be read from this. The sequences are also not uniform: duration, number of changes and oxygen content of the air differ between the studies. The longest follow-up reaches 12 weeks; whether the observed changes persist longer remains open. For blood values such as inflammatory markers or blood lipids it is open whether they are also noticeable for those affected. The single animal study cannot be transferred directly to humans. And whether the treatment works similarly in younger people with mild memory problems is an open question.
4. What This Means in Everyday Life
Anyone reading about the treatment usually encounters reports of better endurance, better blood values or better results in memory tasks. These observations almost always come from programmes in which training or rehabilitation took place in parallel. The treatment itself is described in the studies as well tolerated, even in older and pre-diseased people. Long-term data on repeated use over months or years are still lacking. The results are therefore indications, not certainty. Whether the treatment should be classified as a stand-alone procedure or as a supplement to exercise and rehabilitation is the question that the next studies would have to clarify. It is also open whether the changed blood values and test results are reflected in the everyday lives of those affected.
All details with study numbers and sources: detailed page on Intermittent Hypoxia-Hyperoxia Therapy. For children: Intermittent Hypoxia-Hyperoxia Therapy for children.
Frequently Asked Questions
What happens during the treatment?
One breathes through a mask alternately air with little oxygen and air with much oxygen. The phases change several times. Nothing is introduced into the body and no surgery is performed.
Is the treatment safe?
In the studies it was well tolerated, even in older people with pre-existing conditions. In one study with heart patients before bypass surgery, no serious side effects were reported 4. What it looks like with repeated use over months or years still stands open.
In whom has the treatment been investigated so far?
It has been investigated, among others, in older people with memory or mobility problems 1, in people with metabolic syndrome or severe overweight 26, in heart patients before bypass surgery 4 and in Long-COVID patients during rehabilitation 5. A study on the chronic fatigue disease ME/CFS is still ongoing, results stand out 7.
Sources
- 1Bayer U, Likar R, Pinter G, Stettner H, Demschar S, Trummer B et al. · 2017
- 2Afina AB, Oleg SG, Alexander AB, Ines D, Alexander Yu S, Nikita VV et al. · 2021
- 3Bayer U, Likar R, Pinter G, Stettner H, Demschar S, Trummer B et al. · 2019
- 4Tuter DS, Kopylov PY, Syrkin AL, Glazachev OS, Komarov RN, Katkov AI et al. · 2018
- 5Doehner W, Fischer A, Alimi B, Muhar J, Springer J, Altmann C et al. · 2024
- 6Uzun AB, Iliescu M, Stanciu LE, Nedelcu AD, Petcu A, Popescu MN et al. · 2024
- 7Nochi M, Kristensen SK, Mehrani N, Guerreiro I, Nørholm IMD, Chandra S et al. · 2026
Every statement on this page carries its evidence tier — proven, plausible or hypothesis — and leads to the original work. The decision in the individual case rests with the practitioner; we provide the connections.